Loading
LM-299 is an experimental antibody that blocks two things at once: PD-1, a brake on the immune system, and VEGF, which feeds tumour blood vessels. LaNova Medicines discovered it and Merck licensed it in 2024, where it is called MK-2010.
LM-299 is a bispecific antibody made of an anti-VEGF antibody linked to two C-terminal single-domain anti-PD-1 antibodies, designed to inhibit both PD-1/PD-L1 and VEGF/VEGFR signalling. Merck & Co. announced an exclusive global licence from LaNova Medicines on 14 November 2024, with a USD 588 million payment due at closing; a phase 1 trial was then enrolling in China. LaNova's phase 1/2 trial (NCT06650566) started in October 2024 in advanced solid tumours. ClinicalTrials.gov lists LM-299 as another name for Merck's MK-2010, which Merck is testing in phase 2 trials in advanced solid tumours, alone or with other treatments (NCT07793942) and with sacituzumab tirumotecan (NCT07785609). No results are recorded here.
An antibody against VEGF joined to two small single-domain antibodies against PD-1. It is designed to release the PD-1 brake on immune cells and, at the same time, block the VEGF signal that tumours use to grow new blood vessels. Connects to PD-1 and VEGF / VEGFR.
1.One arm of LM-299 binds PD-1 on the cancer cell.
| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2025-07 | LaNova Medicines to Sino Biopharmaceutical (Chia Tai Tianqing) LaNova Medicines (remaining equity), developer of LM-299 (PD-1 x VEGF, licensed to Merck & Co.) and ADCs | Acquisition | not disclosed | up to about $951m | source |
| 2024-11-14 | LaNova Medicines to Merck & Co. (MSD) LM-299, PD-1 x VEGF bispecific antibody | Licence | $588m | up to $3.3bn | source |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"LM-299" OR ABSTRACT:"LM-299" OR TITLE:"MK-2010" OR ABSTRACT:"MK-2010") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LM-299, not a curated reading list.
Shares Bispecific antibodies and the tags pipeline, deal-asset.
Shares the tags pipeline, deal-asset.
Shares the tags pipeline, deal-asset.
Shares the tags pipeline, deal-asset.
Shares the tags pipeline, deal-asset.
Shares the tags pipeline, deal-asset.
Shares the tags pipeline, deal-asset.
Shares the tags pipeline, deal-asset.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/